Indivior Pharmaceuticals Inc Stock Price, News & Analysis

Indivior (Nasdaq: INDV) published multicenter, open-label trial results in JAMA Network Open on Oct 15, 2025 showing that rapid SUBLOCADE induction (single 4 mg oral buprenorphine followed by same-day SUBLOCADE injection) was well tolerated and produced higher retention at the second injection versus standard induction (≥7 days oral buprenorphine before first injection).

Benefits were seen across the study population and were especially pronounced among fentanyl-positive participants. Administering the second SUBLOCADE injection one week after the first was well tolerated and the safety profile up to injection two was comparable between arms. Study limitations include its open-label design, which could introduce reporting bias.

Indivior (Nasdaq: INDV) has announced plans to change its corporate domicile from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc. (IPI) as the new U.S. parent company. This strategic move follows the company's Nasdaq listing in June 2023 and subsequent delisting from the London Stock Exchange in July 2025.

The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement, where shareholders will receive one new IPI share for each Indivior PLC share. The transaction requires shareholder approval at an extraordinary general meeting in early December 2025, with the scheme expected to become effective in late January 2026. IPI shares will continue trading on Nasdaq under the symbol INDV.

Indivior (NASDAQ: INDV) announced its participation in two upcoming investor conferences in New York City. At the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and participate in a fireside chat at 9:15 a.m. ET. The following day, September 9th, the executives will attend the H.C. Wainwright 27th Annual Global Investment Conference for one-on-one and group meetings.

Indivior (NASDAQ: INDV) reported strong Q2 2025 financial results and raised its full-year guidance. Total net revenue reached $302 million, with SUBLOCADE net revenue growing 9% year-over-year to $209 million. The company has increased its FY 2025 guidance, raising total net revenue expectations to $1,030-$1,080 million from $955-$1,025 million, and adjusted EBITDA guidance to $275-$300 million from $220-$260 million.

Key Q2 metrics include gross margin of 83%, net income of $18 million, and diluted EPS of $0.14. The company initiated its Indivior Action Agenda focusing on SUBLOCADE growth and organizational simplification, completed its LSE delisting to trade exclusively on Nasdaq, and strengthened its executive team with new appointments.

Indivior (Nasdaq: INDV) has completed the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025 at 8:00 a.m. UK time. The delisting includes the removal from both the UK Financial Conduct Authority's Official List and the London Stock Exchange's main market for listed securities.

The company will maintain its primary listing on the Nasdaq Stock Market. To assist shareholders with this transition, Indivior has made available an FAQ document on their investor relations website.

Indivior (Nasdaq/LSE: INDV) has released results from a significant real-world study showing that their extended-release buprenorphine (BUP-XR) treatment demonstrated superior outcomes for opioid use disorder (OUD) patients. The study, published in Drug and Alcohol Dependence Reports, revealed that BUP-XR patients had 57% lower odds of emergency department visits compared to those without medication treatment.

Key findings show that BUP-XR patients experienced significantly lower hospitalization rates (3% vs 5% for daily oral treatment) and notably reduced inpatient costs - nearly five times lower than daily oral buprenorphine patients and ten times lower than untreated patients. Importantly, no opioid overdose-related ED visits were recorded in the BUP-XR group during the six-month study period, compared to 1.2% and 1% overdose rates in other groups.

Indivior (Nasdaq/LSE: INDV) has scheduled its second quarter 2025 financial results announcement for July 31, 2025 at 7:00 a.m. U.S. ET. Following the financial release, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation at 8:00 a.m. U.S. ET.

Investors can access the webcast and presentation materials through the company's website at www.indivior.com. The event will also be accessible via telephone, with registration required for dial-in details. A replay of the presentation will be made available on the company's website afterward.

Indivior (NASDAQ/LSE: INDV) has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience and will oversee Corporate Communications, Government Affairs, Policy and Advocacy.

Prior to joining Indivior, Procter served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE™. She previously held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.

Indivior PLC (Nasdaq/LSE: INDV) announced its inclusion in the U.S. small-cap Russell 2000® Index and Russell 3000® Index, effective June 30, 2025. This inclusion is part of the 2025 Russell indexes reconstitution, which captures the 4,000 largest U.S. stocks based on market capitalization as of April 30.

The company highlighted that 85% of its net revenue in 2024 was generated in the U.S., primarily from SUBLOCADE®, their first-in-class, long-acting injectable medication for opioid use disorder treatment. The Russell indexes are significant benchmarks in the investment community, with approximately $10.6 trillion in assets benchmarked against U.S. Russell indexes as of June 2024.